Role of ADAMs in Epithelial Dysregulation in COPD. Differences Between From Non-smokers, Healthy Smokers and Patients With COPD.
Sponsor study identifier
observational
50
0 countries
N/A
Study Start
May 2009
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
May 2012
Actual (reported)Study Completion
December 2012
Actual (reported)Despite emerging implications for ADAMs (and matrix metalloproteinases (MMPs)) in disease progression, the mechanisms that lead to activation of specific ADAMs (and MMPs) and their actions in chronic obstructive pulmonary disease (COPD) are still incompletely understood. In the current study, the researchers aim to investigate the effects of cigarette smoke on cellular parameters that are relevant for development of COPD and the involvement of ADAM activity in these effects. By studying the effects of ADAM inhibition, the researchers aim to provide novel insights in the role of ADAMs in the development of COPD, which may offer new therapeutic targets for the treatment of COPD.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 2012
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 2009
Date type not reportedThis date has not been verified as actual or estimated.
May 11, 2009
Actual (reported)May 12, 2009
Actual (reported)May 2012
Actual (reported)December 2012
Actual (reported)IL8-production
12 months
Healthy, non-smoking
healthy, ex-smoking
healthy, current-smokers
COPD, ex-smokers
COPD, smokers
Healthy subjects and subjects with COPD
Bronchial brushes
Maarten van den Berge, PhD
University Medical Center Groningen
maarrten van den Berge, PhD
University Medical Center Groningen
Irene Heijink, PhD
University Medical Center Groningen
50 participants (actual enrollment reported by the registry).
First Submitted
May 11, 2009
First Posted
May 12, 2009
Study Start
May 2009
Date type not reportedThis date has not been verified as actual or estimated.
Chronic Obstructive Pulmonary Disease (COPD)-Related Healthcare Utilization and Costs After Discharge From a Hospitalization or Emergency Department Visit on a Regimen of Fluticasone Propionate-Salmeterol Combination Versus Other Maintenance Therapies
Contact the study team to confirm eligibility.
Primary Completion
May 2012
Actual (reported)Study Completion
December 2012
Actual (reported)Last Updated
January 16, 2015
Record last verified: 2015-01
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: